Analysis of Pharmacokinetic/Pharmacodynamic Parameters and Dosage Regimen of Posaconazole against <i>Candida</i>spp. and <i>Aspergillus</i>spp. Using Monte Carlo Simulation

• 作者: Jingyi Zhao Junhui Hu Xinhong Zhao Ying Wang Yinhui Yao
• 来源期刊: 药理与制药(英文)
• 学科: 医学
• 关键词: POSACONAZOLE Monte Carlo Simulation CANDIDA spp. ASPERGILLUS spp. Pharmacokinetics/Pharmacodynamics
• 年，卷（期）: 2020,（1）
• 页码范围: 17-28
• 页数: 12页
• 分类号: R97

摘要

Invasive fungal infections (IFI) have recently become increasingly more prevalent, resulting in an increased risk of morbidity and mortality. Both Candida spp. and Aspergillus spp. are major causes of IFI. In this study, we aimed to evaluate the cumulative fraction of response of various dosage regimens of posaconazole against nine Candida spp. and six Aspergillus spp. in both children and adults. Monte Carlo simulation (MCS) was performed to optimize selection of posaconazole dosage regimens. For children, a dosage regimen of 120 mg/m2 posaconazole tid was sufficient to treat fungal infections caused by all six Aspergillus spp. and six of the nine Candida spp. (but was not effective against C. glabrata, C. guilliermondii and C. krusei). In contrast, a 400 mg dosage regimen of posaconazole bid achieved the target pharmacokinetic/pharmacodynamics (PK/PD) parameters against all six Aspergillus spp. and eight of the nine Candida spp. (but was not effective against C. glabrata) in the adults. Dosage regimens of 50 mg bid, 100 mg bid, or 200 mg bid were not effective. Posaconazole dosage regimens are likely to achieve their desired PK/PD targets against Candida spp. and Aspergillus spp. in both children and adults.